Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.

Abstract excerpt

Interest in genomic testing for the selection of cancer therapy is growing. However, the cost of genomic testing has not been well studied. We sought to determine the price of identifying mutations and copy number alterations (CNAs) in theoretically actionable genes across multiple tumor types. We reviewed data from The Cancer Genome Atlas to determine the frequency of alterations in nine tumor types. We used...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Costs and Cost Analysis
• Share to DNA Copy Number Variations